How does too much LDL or ApoB lead to clogged arteries?
Too many LDL particles and too much apoB in your blood set off a chain reaction that slowly clogs arteries. The evidence for this is strong and causal.
LDL particles actively penetrate the artery wall through its innermost cell layer. Once inside, they bind to sticky protein structures within the vessel wall via the apoB protein that each particle carries on its outer surface. Trapped in this way, they can no longer be removed.
Then things go wrong. The trapped LDL undergoes chemical changes such as oxidation. The immune system dispatches defence cells that engulf the damaged LDL. But the normal 'stop' signal does not work here: the defence cells become packed with fat and turn into foam cells. When those cells die, they leave behind a fat-rich, inflamed mass -- the core of a dangerous plaque. Cholesterol crystals and dead cell debris accumulate and make the plaque unstable.
The risk depends not only on how much cholesterol is in your blood, but also on how many LDL particles are circulating. Each particle carries exactly one apoB protein, so the total apoB in your blood tells you directly how many harmful particles there are. Two people can have the same LDL value but a very different number of particles and therefore a very different risk. The European Society of Cardiology therefore recognises apoB as a more accurate measure of risk than LDL cholesterol1.
Besides ordinary LDL, there are additional apoB-carrying particles that cause damage. Triglyceride-rich remnant particles are less numerous, but considerably more harmful per particle. In a study of more than 17,000 people without known cardiovascular disease, followed for nearly nineteen years, high remnant cholesterol increased the risk of a cardiovascular event by 65%, even when LDL and apoB had already been accounted for2. Their exact mechanism of action in humans is not yet fully understood.
In people with lupus the risk rises further: at the time of diagnosis around 30% already have elevated LDL and apoB levels, and after three years that figure is approximately 60%3. On top of the lipids, inflammatory processes and immune antibodies accelerate plaque formation. Mouse studies show that a liver protein that suppresses apoB production offers protection against arterial calcification, but this has so far only been demonstrated in animals4.
Based on two mechanistic review studies (PMID 39743565, 6361811), one large prospective cohort study (more than 17,000 people, PMID 34293083), one guideline-supporting analysis from the European Society of Cardiology (PMID 36216435), one lupus observational study (PMID 28168401), and one mouse study (PMID 41446920). The core mechanism of LDL retention and plaque formation rests on strong causal evidence. The contribution of remnant cholesterol is robustly associated, but the causal mechanism in humans has not yet been fully elucidated. The target involving the liver protein has been demonstrated exclusively in animal research.